The Opposites Attract Study of viral load, HIV treatment and HIV transmission in serodiscordant homosexual male couples: design and methods by Benjamin R Bavinton et al.
Bavinton et al. BMC Public Health 2014, 14:917
http://www.biomedcentral.com/1471-2458/14/917STUDY PROTOCOL Open AccessThe Opposites Attract Study of viral load, HIV
treatment and HIV transmission in serodiscordant
homosexual male couples: design and methods
Benjamin R Bavinton1*, Fengyi Jin1, Garrett Prestage1,2, Iryna Zablotska1, Kersten K Koelsch1,3, Nittaya Phanuphak4,
Beatriz Grinsztejn5, David A Cooper1,3, Christopher Fairley6,7, Anthony Kelleher1,3,8, Kathy Triffitt1, Andrew E Grulich1,
for the Opposites Attract Study GroupAbstract
Background: Studies in heterosexual HIV serodiscordant couples have provided critical evidence on the role of HIV
treatments and undetectable viral load in reducing the risk of HIV transmission. There is very limited data on the
risk of transmission from anal sex in homosexual male serodiscordant couples.
Methods/Design: The Opposites Attract Study is an observational prospective longitudinal cohort study of male
homosexual serodiscordant partnerships running from 2012 to 2015 and conducted in clinics throughout Australia,
Brazil and Thailand. Couples attend two or more clinic visits per year. The HIV-positive partner’s viral load is tested
and the HIV-negative partner is tested for HIV antibodies at every clinic visit. Results from any tests for sexually
transmitted infections are also collected. Detailed behavioural questionnaires are completed by both partners at the
time of each visit. The primary research question is whether HIV incidence is lower in those couples where the
HIV-positive partner is receiving HIV treatment compared to couples where he is not receiving treatment. A
voluntary semen sub-study will examine semen plasma viral load in a subsample of HIV-positive partners in Sydney,
Rio de Janeiro and Bangkok. In cases of seroconversion of the initially HIV-negative partner, phylogenetic analysis
will be conducted at the end of the study on virus from stored blood samples from both partners to determine if
the infection came from the HIV-positive study partner. Men in new serodiscordant relationships will specifically be
targeted for recruitment.
Discussion: This study will provide critical data on the reduction in HIV transmission risk associated with being on
HIV treatment in homosexual male serodiscordant couples in different regions of the world. Data from men in new
relationships will be particularly valuable given that the highest transmission risk is in the first year of serodiscordant
relationships. Furthermore, the detailed behavioural and attitudinal data from the participant questionnaires will
allow exploration of many contextual factors associated with HIV risk, condom use and the negotiation of sexual
practice within couples.
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Studies in heterosexual HIV serodiscordant couples have
provided critical evidence on the role of HIV treatments
and undetectable viral load in reducing the risk of HIV
transmission. A number of observational studies, pri-
marily in African heterosexual serodiscordant couples,
have demonstrated a link between HIV treatment, un-
detectable viral load and reduced transmission risk [1].
In 2011, the early results of a randomised clinical trial,
HPTN 052, provided conclusive evidence that when the
HIV-positive partner is on antiretroviral therapy (ART),
transmission risk is dramatically reduced by 96% in
heterosexual serodiscordant couples [2].
The strategy of reducing HIV transmission risk by pla-
cing the HIV-positive partner on ART irrespective of
stage of HIV infection has widely become known as
‘treatment as prevention’ (TasP) [3-5]. Despite several
studies demonstrating the effectiveness of TasP in het-
erosexual serodiscordant couples, there is currently no
conclusive evidence on the relationship between ART
and transmission in male homosexual serodiscordant
couples [6,7]. Given that the risk of HIV transmission
via anal intercourse is about 10 times greater than for
vaginal intercourse [8], it cannot be assumed that the
effectiveness of TasP will be identical for the two types
of sex. As anal intercourse is not uncommon among
heterosexuals (for example, 20.9% of adult heterose-
xual men and 15.1% of adult heterosexual women in
Australia report anal sex in their lifetime [9]), findings in
homosexual men may also have broader relevance for
the effectiveness of TasP in heterosexuals.
Internationally, only one study has reported findings
on TasP in homosexual male serodiscordant couples: the
Partners of people on ART – a New Evaluation of the
Risks (PARTNER) Study in the United Kingdom and
Europe [7]. The interim analysis presented in early 2014
provided promising but not yet conclusive results.
Amongst 308 homosexual male serodiscordant couples,
no phylogenetically linked HIV transmissions were ob-
served in two years of follow-up. However, the results
were statistically consistent with a possible risk of up to
1.17% per year for couples who reported any unpro-
tected anal intercourse (UAI), and up to 1.97% per year
in those couples where receptive UAI (with or without
ejaculation) was reported [10].
Research questions
The Opposites Attract Study addresses the follo-
wing questions, in serodiscordant male homosexual
partnerships:
1. Is HIV incidence lower in those couples where the
HIV-positive partner is receiving ART, compared
with not receiving ART?2. Is HIV incidence higher in those couples where the
HIV-positive partner has detectable blood plasma
viral load (BPVL) compared to those couples where
he has undetectable BPVL?
3. Is BPVL used in negotiating unprotected anal
intercourse within couples?
4. Is HIV transmission possible when the HIV-positive
partner has undetectable BPVL but either partner
has a relevant sexually transmitted infection (STI)?
5. In a subsample of couples, is HIV incidence
related to semen plasma viral load (SPVL) in the
HIV-positive partner?
6. In a subsample of HIV-positive men, is BPVL
associated with SPVL?Methods/Design
Summary of study design
Opposites Attract is an observational prospective longi-
tudinal cohort study of male homosexual serodiscordant
partnerships, coordinated by the Kirby Institute at the
University of New South Wales, Australia. The study is
conducted through several high HIV caseload clinics
throughout Australia and in Bangkok, Thailand and Rio
de Janeiro, Brazil. The study involves attendance at two or
more clinic visits per year followed by completion of on-
line computer-assisted self-interviews after each visit. At
clinic visits, data are collected on HIV BPVL and CD4
T-cell count in the HIV-positive partner, HIV antibodies
in the HIV-negative partner, and STI test results in both
partners. Samples of blood for storage of plasma, serum
and buffy coat are taken from both partners at baseline,
once a year during follow-up (from the HIV-positive
partner only), and at seroconversion of the initially HIV-
negative partner should that occur. Anal swabs are taken
for storage from the HIV-negative partner at baseline and
if seroconversion occurs. In a voluntary sub-study at sites
in Sydney, Bangkok and Rio de Janeiro, HIV-positive part-
ners attending clinics are invited to provide a semen sam-
ple at the time of each clinic visit. Enrolment commenced
in April 2012 and under current funding arrangements,
follow-up will continue until the end of 2015.Sample size
The sample size calculations were based on the hypo-
theses relating to BPVL and HIV incidence. The calcula-
tions were performed using data on HIV incidence in
HIV-negative men with HIV-positive primary regular
partners from previous Kirby Institute studies [11,12]. It
was not possible to be as precise in estimating the
study’s power to test hypotheses concerning SPVL. Two
types of power calculation were performed, to consider
situations in which either zero or at least one linked
seroconversion occur in the study. This was because the
Table 1 Serodiscordant couples sample size calculations
Percentage of HIV
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missions within the serodiscordant couples.
1. At least 1 phylogenetically linked HIV seroconversion
is identified in the cohort:60% 0.75 18 631
0.85 11 436
0.95 7 305
70% 0.75 15 624
0.85 9 413
0.95 5 272
80% 0.75 14 692
0.85 7 429
0.95 4 256
90% 0.75 17 1008
0.85 7 563
0.95 3 276We examined various plausible scenarios where the
study would have at least 80% power to detect at
least a 75% reduction in the incidence of HIV cases
in those whose partners have undetectable as
compared to detectable BPVL. For the primary
power calculation, based on Australian research we
assumed that 60% of HIV-positive partners will have
undetectable BPVL [13]. We also assumed that the
HIV incidence in HIV-negative men whose
partners have detectable BPVL will be 5.0 per
100 person-years. This assumption was derived from
the incidence observed in the Health In Men (HIM)
study, our previous cohort study of HIV-negative
gay men in Sydney conducted between 2001 and
2007 [12]. The incidence of HIV in negative men
whose partners had detectable viral load could not
be directly calculated in the HIM study due to
lack of completeness of data on the BPVL of
HIV-positive partners. However, we estimated an
incidence of around 5 per 100 person-years in
partnerships where the HIV-positive partner had
detectable BPVL. This was based on two factors: the
HIV incidence of 2.2 per 100 person-years in men
with HIV-positive primary regular partners in HIM
[14], and the fact that in 60% of these relationships,
the BPVL would have been undetectable and
therefore have lower HIV incidence than 2.2 per
100 person-years. In this scenario, we estimated 18
incident HIV infections would be required, requiring
a total of 631 couple-years of follow-up to enable
80% statistical power to detect at least a 75%
reduction in HIV incidence in men whose partners
have undetectable BPVL.
For other scenarios we assumed greater proportions
of HIV-positive partners with undetectable viral
load. This was based on the possibility that more
HIV-positive men may commence treatment
following the publication of results from TasP
studies in heterosexuals. These scenarios and the
associated sample sizes are presented in Table 1.
In summary, a sample size of 640 couple-years of
follow-up will result in a statistical power of
approximately 80% even if the proportion of
HIV-positive partners with undetectable
BPVL increases to 70% or 80%. However, if this
proportion increases to 90% of HIV-positive men,
the study will be powered to detect an 80%
reduction in HIV incidence in negative men whose
partners have undetectable BPVL, which means theHIV incidence in these men will be 1.0 per 100
person-years or lower.
2. No phylogenetically linked HIV seroconversions are
identified in the cohort (transmission rate = 0 per
100 person-years):
As mentioned, recent research findings relating to
the effectiveness of TasP [2,10] may lead to a
greater percentage of HIV-positive gay men in
serodiscordant relationships electing to receive
ART and thus having undetectable BPVL. For the
purposes of this calculation, we have assumed
that this may increase to 80% or 90% of all
serodiscordant couples. If this is the case, and if
effective antiretroviral treatment is as successful at
reducing the risk of HIV transmission in gay
men as was found among heterosexuals in HPTN
052 (i.e. 96% reduction), we may find no phylogene-
tically linked seroconversions in this study. In this
case, the analysis will focus on calculating the upper
limit of the confidence interval of an HIV incidence
of 0 per 100 person years in couples where the
HIV-positive partner has undetectable BPVL.
Assuming that the study achieves 640 couple-years
of follow-up, and no phylogenetically related
transmissions are documented, the upper limit of
the 97.5% single-sided HIV incidence in partnerships
where the HIV-positive partner has undetectable
BPVL would be 0.72 and 0.64 per 100 person-years,
if the proportion of HIV-positive participants with
undetectable BPVL is 80% and 90% respectively.
Eligibility
Homosexual men in sexual partnerships meeting the fol-
lowing criteria are eligible to enroll in the study: (1) Both
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positive and the other partner HIV-negative at baseline;
(3) Partners must have anal sex with each other at least
once per month on average; (4) Partners must believe
they will still be having anal sex with each other by the
time of the HIV-positive partner’s next viral load test
(that is, between three to six months after baseline); and
(5) Both partners must agree to attend clinic visits at
least twice per year. HIV-positive partners can enroll in
the study irrespective of whether they are taking ART or
not, or whether their BPVL is undetectable or detect-
able. Couples can enroll irrespective of whether they
engage in unprotected or protected anal intercourse with
each other.
Clinical sites
As of September 2014, fourteen high HIV caseload pub-
lic (n=6) and private (n=8) clinics in Australia are par-
ticipating in the study, along with one clinic in Rio de
Janeiro, Brazil, and another clinic in Bangkok, Thailand.
New sites may be initiated at a later time.
Recruitment
Clinics are free to employ a range of recruitment stra-
tegies to identify and recruit potential participants,
depending on what is deemed appropriate for each
clinic. Mostly, couples are recruited when clinicians raise
the study directly with HIV-positive patients or HIV-
negative patients known to have an HIV-positive regular
partner. Interested patients are given information about
the study and are asked to speak to their regular partner
about participation. They are contacted by the clinic-
based study coordinator and an enrolment visit is
arranged if the couple is both interested and eligible.
Community-based study promotion is also implemented
in the form of print and online advertising, attendanceTable 2 Procedures associated with each clinic visit
Baseline visit First visit of calen
HIV-Positive partner
Viral load test X X
CD4 Count X X
STI tests3 X X
Blood samples for storage X X
Semen sample (optional)2 X X
HIV-Negative partner
HIV antibody test X X
STI tests3 X X
Blood samples for storage X
Anal swab for storage X
1Seroconversion visits only occur if the HIV-negative partner seroconverts during fo
2The semen sub-study is only available at certain sites.
3At Australian clinical sites, STI tests are conducted as indicated. In Brazil and Thailaand/or presentations at community events, and engage-
ment with community-based partner organisations.
Enrolment and clinic visits
In Australia, couples are enrolled at the clinic the HIV-
positive partner attends for routine clinical management.
In Brazil and Thailand, couples are enrolled at the study
clinic. The study is clearly explained, and consent forms
signed. Participants must sign the consent forms while
their partner is outside the room, to minimise the risk of
coerced participation. Both partners complete an HIV
transmission knowledge quiz and education process to
ensure they understand how HIV is transmitted in the
context of serodiscordant male-to-male sex. They are
encouraged to read the Opposites Attract HIV transmis-
sion factsheet before attending the enrolment visit.
Once enrolled, both partners undergo a baseline clinic
visit, involving pathology samples testing (viral load,
CD4, HIV antibodies, STIs) and the collection of bio-
logical samples for storage. Follow-up visits occur each
time regular viral load monitoring of the HIV-positive
partner occurs, a minimum of two times per year. Part-
ners do not need to attend their clinic visits at the same
time. However, they must attend within two weeks of
each other.
Table 2 indicates all procedures associated with each
clinic visit. A viral load test is required for an HIV-
positive partner’s visit to be considered a study visit,
while an HIV antibody test is required for an HIV-
negative partner’s visit to be considered a study visit.
In Australia, STI tests are conducted as indicated by
Australian guidelines [15]. In Brazil and Thailand,
syphilis, gonorrhoea and chlamydia tests are conducted
at every study visit. At certain visits, extra blood samples
are taken for storage from both partners, and an extra











nd, they are conducted at every visit.
Table 3 Questionnaire content for HIV-positive and
HIV-negative partners
HIV-Positive partner HIV-Negative partner
Demographics Demographics
HIV diagnosis and treatment HIV testing
ART adherence STI testing and symptoms
STI testing and symptoms Relationships and communication
Relationships and communication Relationship agreements
Attitudes Partner viral load
Study involvement and motivations Sexual behaviour with study partner
Sexual behaviour with other partners
Group sex
PEP and PrEP use and knowledge
Attitudes
Reasons for using/not using condoms
Study involvement and motivations
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and shipped to the central laboratory in batches. The
blood samples allow for later phylogenetic testing of the
partners’ virus in cases of seroconversion of the initially
HIV-negative partner. In addition, the specimens may
potentially be used to identify genetic factors associated
with resistance to HIV acquisition in HIV-negative part-
ners. The anal swabs are taken to later test for rectal
herpes simplex virus (HSV) and human papillomavirus
(HPV). In Sydney, Rio de Janeiro and Bangkok, HIV-
positive participants can elect to join the Semen Sub-
Study whereby they provide a semen sample at the time
of each clinic visit. The semen samples are processed
and stored for later viral load and phylogenetic testing.
Data collection
Data are collected via electronic case record forms
(eCRFs) completed by clinic staff and online computer-
assisted self-interview from both HIV-positive partners
and HIV-negative partners. The eCRFs include: enrol-
ment information, clinic visit information (including the
HIV-positive partner’s ART regimen), and pathology re-
sults information. For HIV-positive partners partici-
pating in the Semen Sub-Study, further information is
entered upon receipt of the sample. Participants are
asked to complete their questionnaires at the clinic visit,
or within 48 hours of the visit. As the questionnaires are
online, they can be accessed by participants in their
homes. Clinicians and clinic staff do not have access to
the behavioural questionnaire information regarding
their patients, and participants are explicitly informed of
this. Table 3 indicates the content categories of the
HIV-positive partner and HIV-negative partner ques-
tionnaires. Baseline and follow-up questionnaires are
very similar. Finally, all initially HIV-negative partners
who acquire HIV during follow-up will be invited to
participate in a qualitative interview regarding their
seroconversion. Further qualitative interviews with other
study participants may also be conducted as part of a
sub-study.
HIV seroconversion of initially HIV-negative partners
In cases of HIV seroconversion among initially HIV-
negative participants, each clinic will follow its standard
approach, typically including immediate referral to an
HIV specialist for further testing and monitoring, refer-
ral to professional and peer-based support services, and
discussion of treatment options. The study protocol does
not mandate any specific approach to how clinics should
deal with HIV seroconversion.
At the end of the study, phylogenetic analysis will be
conducted on paired stored blood samples from both
partners. Epidemiological relationships will be estab-
lished by analyses of env and gag-pol sequences derivedfrom plasma as well as PBMC from these blood samples.
Sequence alignment will be performed by using either
Clustal X or MUSCLE software. Phylogenetic analyses
including patient derived sequences and background se-
quences derived from the Los Alamos database will assess
linkage between different viruses by inferred maximum
likelihood phylogeny, neighbour joining methods, pairwise
distances, Bayesian inference and bootstrap analyses [16].
Tree visualisation will be performed using, for example,
TreeView or UGENE software.
Data analysis
The primary analyses aim to determine if HIV incidence
is reduced in the HIV-negative partner when the HIV-
positive partner: (1) is taking ART compared to not taking
ART, and (2) has undetectable viral load compared to de-
tectable viral load. These incidence rates will be calculated
by dividing the number of phylogenetically linked sero-
conversions for each group by the total number of
person-years of follow-up for that group. If there are no
phylogenetically linked seroconversions, the upper limit of
the confidence interval around a transmission rate of zero
will be determined. Given that laboratories utilise different
assays for viral load testing which have various lower
limits of detection (e.g. 20, 40, 50, or 150 copies per mL),
the precise definition of ‘undetectable’ and ‘detectable’
BPVL differs across sites. This will be taken into account
in analysis, and a standardised cut-off may be used for di-
rectly measured BPVL (e.g. less than 400 copies per mL).
Two of the study questions relate to SPVL. First, in
the subsample of couples included in the Semen Sub-
Study, HIV incidence will be compared between couples
with detectable versus undetectable SPVL in the HIV-
positive partner. Second, within the HIV-positive partners
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will be compared at each study visit. HIV RNA levels in
seminal plasma will be determined using an adaptation of
an in-house assay for separation of seminal plasma from
human samples and the COBAS® AmpliPrep/COBAS®
TaqMan® system.
The behavioural and attitudinal data collected from
the participant questionnaires will allow for both cross-
sectional and longitudinal analyses. A key focus will be
on the question of whether gay men in serodiscordant
relationships use condoms less often when the HIV-
positive partner has undetectable viral load [17]. This
will be explored both through directly measured and
perceived viral load, both categorically in terms of those
who have/do not have UAI as well as by the number and
type (insertive/receptive and with/without ejaculation) of
acts of UAI, and in relation to attitudes regarding TasP,
communication within relationships, and relationship
agreements about viral load and sexual practice.
The study data will also allow examination of: the per-
contact risk of HIV infection by acts of UAI; concor-
dance of perceived and actual viral load results; impacts
of adherence on viral load; use of pre-exposure pro-
phylaxis and post-exposure prophylaxis in HIV-negative
partners; comparison of attitudes within couples; the
effect of STIs on behaviour and HIV risk; and charac-
teristics of ART use in HIV-positive partners (i.e. star-
ting ART, changing regimens, side effects).
Ethical committee review
Opposites Attract is conducted according to the Australian
National Statement on Ethical Conduct in Human Re-
search [18] and the World Medical Association Decla-
ration of Helsinki [19]. It has been approved by several
human research ethics committees (HRECs), including at
St Vincent’s Hospital (Sydney), The Alfred Hospital
(Melbourne), the Prince Charles Hospital (Brisbane), the
University of New South Wales (Sydney), the Comitê
de Ética em Pesquisa do Instituto de Pesquisa Clinica
Evandro Chagas (Rio de Janeiro), and Chulalongkorn
University’s Faculty of Medicine (Bangkok). In Australia,
the study was also approved by hospital research gover-
nance offices before initiation in the public clinics. Further,
the study was approved by two ethical review committees
based at HIV community-based organisations. Further ap-
provals will be sought if new sites are initiated.
HIV transmission and legal prosecution
In many countries, HIV transmission is criminalised via
public health and/or criminal legislation. The study team
sought detailed written legal advice pertaining to each
Australian state in which the study is being conducted.
Advice was also sought from the international sites
regarding local legislation. Several legal protections forHIV-positive partners were implemented. First, all HIV-
negative partners are required to sign a declaration
stating that they are aware of their sexual partner’s HIV-
positive serostatus. Second, at study enrolment, all par-
ticipants must undertake a quiz on HIV transmission to
ensure a high level of knowledge regarding HIV risk in
relation to condom use, sexual positioning, STIs, cir-
cumcision, withdrawal prior to ejaculation, oral sex, and
awareness of post-exposure prophylaxis. If any questions
are answered incorrectly, study staff members provide
detailed HIV transmission education, and this is docu-
mented. Third, at baseline, participants consent to not
receiving the results of phylogenetic analysis that would
indicate whether or not the new infection was a linked
transmission. These results will not be provided to par-
ticipants or their clinicians under any circumstances.
Fourth, questionnaires do not ask HIV-positive partners
to report sexual risk behaviour; this is asked of the HIV-
negative partner only.
Discussion
While there is strong evidence for the effectiveness of
ART to substantially reduce the risk of HIV transmission
in heterosexual serodiscordant couples, there is very
limited published evidence on TasP within homosexual
male serodiscordant couples or in relation to anal inter-
course. Opposites Attract and the PARTNER Study [7]
appear to be the only two clinical studies exploring these
questions. The PARTNER Study focuses on measuring
the HIV incidence in both heterosexual and homosexual
serodiscordant couples having unprotected anal and/or
vaginal intercourse, and is restricted to couples where
the HIV-positive partner is receiving ART at baseline. By
contrast, Opposites Attract will allow the calculation of
HIV incidence in couples where HIV-positive partners
are on ART or not on ART, and with undetectable
versus detectable BPVL (and SPVL in a subsample of
couples). Furthermore, the detailed behavioural and
attitudinal data from the participant questionnaires will
allow exploration of many contextual factors associated
with HIV risk, condom use and the negotiation of sexual
practice within couples.
Measuring the effect of ART on transmission is im-
pacted by whether serodiscordant couples have unpro-
tected intercourse with each other. In Opposites Attract,
the decision was made not to restrict enrolment to those
couples reporting UAI with each other in the months
before baseline (as in the PARTNER Study). This was be-
cause in a pilot study we conducted in Melbourne, it
was found that participants were wary of enrolling or ex-
pressing interest in the study if they were required to re-
port having UAI with each other to their clinician. Thus,
the eligibility criterion for the main study was changed
to the couples having anal intercourse (protected or
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average. The level of risk within the cohort will be moni-
tored over time and changes may be made to this criter-
ion in the future if necessary.
Furthermore, in preparation for Opposites Attract, we
analysed cohort data of HIV-negative men in Sydney
and found that amongst HIV-negative who reported
being in a serodiscordant relationship of one year or less,
the HIV incidence was approximately 6 per 100 person-
years as compared to much lower incidence in those
who reported longer relationships, suggesting that the
riskiest period for HIV-negative men in serodiscordant
relationships is the first year of the relationship [14,20].
This may be due to the relatively higher frequency of sex
in newer relationships [21,22]. Additionally, partners
who stay negative after longer periods of time in a sero-
discordant relationship may have reduced susceptibility
of some kind, such as having a protective genetic pre-
disposition or acquired immunity through repeated ex-
posure [23]. In any case, this finding suggests that in
Opposites Attract, men in new relationships need to be
targeted to ensure that the effect of ART on transmis-
sion can be measured. Restricting participation to ‘stable’
couples that have been together for a specified period of
time may have the effect of underestimating the true
HIV incidence as the studies may recruit couples once
the riskiest period has already passed. Additionally, this
may suggest that studies would benefit from targeting
non-romantic yet regular sexual relationships (e.g. collo-
quially known as ‘fuckbuddy’ relationships [24]) as many
‘committed’ homosexual male relationships may begin in
this way [25].
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